Cargando…

Integrating systematic pharmacology-based strategy and experimental validation to explore mechanism of Tripterygium glycoside on cholangiocyte-related liver injury

OBJECTIVE: Tripterygium glycoside (TG) is widely used in clinical practice for its multiple bioactivities including anti-inflammatory and immunosuppressive effects. However, emerging studies have frequently reported TG-induced adverse reactions to multiple organs, especially liver. Here, this study...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Yajing, Li, Sen, Xue, Xiaoyong, Wang, Ting, Li, Xiaojiaoyang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9669401/
https://www.ncbi.nlm.nih.gov/pubmed/36405068
http://dx.doi.org/10.1016/j.chmed.2022.02.006
_version_ 1784832089334480896
author Li, Yajing
Li, Sen
Xue, Xiaoyong
Wang, Ting
Li, Xiaojiaoyang
author_facet Li, Yajing
Li, Sen
Xue, Xiaoyong
Wang, Ting
Li, Xiaojiaoyang
author_sort Li, Yajing
collection PubMed
description OBJECTIVE: Tripterygium glycoside (TG) is widely used in clinical practice for its multiple bioactivities including anti-inflammatory and immunosuppressive effects. However, emerging studies have frequently reported TG-induced adverse reactions to multiple organs, especially liver. Here, this study aimed to investigate the mechanism of liver damage induced by TG and explore representative components to reflect TG hepatotoxicity. METHODS: Network pharmacology was used to determine the potential targets of bile duct injury caused by TG. Next, the hepatotoxic effects of TG, triptolide (TP) and celastrol (CEL) were investigated and compared in vivo and in vitro. Liver function was determined by measuring serum transaminase and histopathology staining. The cell proliferation and apoptosis were determined by cell viability assay, scratch assay and flow cytometry. The expression of gene of interest was determined by qPCR and Western blot. RESULTS: Based on the network pharmacological analysis of 12 bioactive ingredients found in TG, a total of 35 targets and 15 pathways related to bile duct injury were obtained. Both TG and TP resulted in cholangiocyte damage and liver injury, as illustrated by increased levels of serum transaminase and oxidative stress, stimulated portal edema and lymphocytic infiltration and decreased expression of cholangiocyte marker, cytoskeletal 19. In addition, TG and TP inhibited cell proliferation and migration, arrested cell cycle and promoted Caspase-dependent apoptosis of cholangiocytes via suppressing the phosphorylation of extracellular regulated protein kinases 1/2 (ERK1/2) and protein kinase B (AKT). While, CEL at equivalent dosage had no obvious hepatotoxicity. CONCLUSION: We revealed that TG-stimulated liver injury was specifically characterized by cholangiocyte damage and TP might be the decisive ingredient to reflect TG hepatotoxicity. Our results not only provide novel insights into the mechanism underlying the hepatotoxicity effects of TG but also offer reference for clinical rational use of TG.
format Online
Article
Text
id pubmed-9669401
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-96694012022-11-18 Integrating systematic pharmacology-based strategy and experimental validation to explore mechanism of Tripterygium glycoside on cholangiocyte-related liver injury Li, Yajing Li, Sen Xue, Xiaoyong Wang, Ting Li, Xiaojiaoyang Chin Herb Med Original Article OBJECTIVE: Tripterygium glycoside (TG) is widely used in clinical practice for its multiple bioactivities including anti-inflammatory and immunosuppressive effects. However, emerging studies have frequently reported TG-induced adverse reactions to multiple organs, especially liver. Here, this study aimed to investigate the mechanism of liver damage induced by TG and explore representative components to reflect TG hepatotoxicity. METHODS: Network pharmacology was used to determine the potential targets of bile duct injury caused by TG. Next, the hepatotoxic effects of TG, triptolide (TP) and celastrol (CEL) were investigated and compared in vivo and in vitro. Liver function was determined by measuring serum transaminase and histopathology staining. The cell proliferation and apoptosis were determined by cell viability assay, scratch assay and flow cytometry. The expression of gene of interest was determined by qPCR and Western blot. RESULTS: Based on the network pharmacological analysis of 12 bioactive ingredients found in TG, a total of 35 targets and 15 pathways related to bile duct injury were obtained. Both TG and TP resulted in cholangiocyte damage and liver injury, as illustrated by increased levels of serum transaminase and oxidative stress, stimulated portal edema and lymphocytic infiltration and decreased expression of cholangiocyte marker, cytoskeletal 19. In addition, TG and TP inhibited cell proliferation and migration, arrested cell cycle and promoted Caspase-dependent apoptosis of cholangiocytes via suppressing the phosphorylation of extracellular regulated protein kinases 1/2 (ERK1/2) and protein kinase B (AKT). While, CEL at equivalent dosage had no obvious hepatotoxicity. CONCLUSION: We revealed that TG-stimulated liver injury was specifically characterized by cholangiocyte damage and TP might be the decisive ingredient to reflect TG hepatotoxicity. Our results not only provide novel insights into the mechanism underlying the hepatotoxicity effects of TG but also offer reference for clinical rational use of TG. Elsevier 2022-09-27 /pmc/articles/PMC9669401/ /pubmed/36405068 http://dx.doi.org/10.1016/j.chmed.2022.02.006 Text en © 2022 Tianjin Press of Chinese Herbal Medicines. Published by ELSEVIER B.V. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original Article
Li, Yajing
Li, Sen
Xue, Xiaoyong
Wang, Ting
Li, Xiaojiaoyang
Integrating systematic pharmacology-based strategy and experimental validation to explore mechanism of Tripterygium glycoside on cholangiocyte-related liver injury
title Integrating systematic pharmacology-based strategy and experimental validation to explore mechanism of Tripterygium glycoside on cholangiocyte-related liver injury
title_full Integrating systematic pharmacology-based strategy and experimental validation to explore mechanism of Tripterygium glycoside on cholangiocyte-related liver injury
title_fullStr Integrating systematic pharmacology-based strategy and experimental validation to explore mechanism of Tripterygium glycoside on cholangiocyte-related liver injury
title_full_unstemmed Integrating systematic pharmacology-based strategy and experimental validation to explore mechanism of Tripterygium glycoside on cholangiocyte-related liver injury
title_short Integrating systematic pharmacology-based strategy and experimental validation to explore mechanism of Tripterygium glycoside on cholangiocyte-related liver injury
title_sort integrating systematic pharmacology-based strategy and experimental validation to explore mechanism of tripterygium glycoside on cholangiocyte-related liver injury
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9669401/
https://www.ncbi.nlm.nih.gov/pubmed/36405068
http://dx.doi.org/10.1016/j.chmed.2022.02.006
work_keys_str_mv AT liyajing integratingsystematicpharmacologybasedstrategyandexperimentalvalidationtoexploremechanismoftripterygiumglycosideoncholangiocyterelatedliverinjury
AT lisen integratingsystematicpharmacologybasedstrategyandexperimentalvalidationtoexploremechanismoftripterygiumglycosideoncholangiocyterelatedliverinjury
AT xuexiaoyong integratingsystematicpharmacologybasedstrategyandexperimentalvalidationtoexploremechanismoftripterygiumglycosideoncholangiocyterelatedliverinjury
AT wangting integratingsystematicpharmacologybasedstrategyandexperimentalvalidationtoexploremechanismoftripterygiumglycosideoncholangiocyterelatedliverinjury
AT lixiaojiaoyang integratingsystematicpharmacologybasedstrategyandexperimentalvalidationtoexploremechanismoftripterygiumglycosideoncholangiocyterelatedliverinjury